The Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, by Drugs (Benazepril, Perindopril, Trandfolapril, Captopril, Enalapril, Lisinopril, Ramipril, and Others), by Application (Hypertension, Coronary Artery Disease, Heart Failure, Chronic Kidney Disease, Scleroderma, and Migraine), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), was valued at US$ 11,693.6 million in 2017, and is projected to exhibit a CAGR of 0.8%, during the forecast period (2018 - 2026), as highlighted in a new report published by.

Increasing product launches for ACE inhibitor drug class is expected to boost the angiotensin converting enzymes (ACE) inhibitors market growth. For instance, in February 2014, Martindale Pharma, launched new Captopril oral liquid solution for the treatment of chronic heart failure in newborns, infants, and children. Captopril, an angiotensin converting enzyme (ACE) inhibitor, is widely used for the treatment of hypertension, congestive heart failure, and kidney problems. Captopril is responsible for conversion of Angiotensin I to Angiotensin II. Through this conversion, Captopril helps to maintain blood pressure of the body. Increasing drug approvals from healthcare regulatory authorities for the treatment of hypertension is expected to drive the market growth. For instance, in March 2018, January 2015, the U.S. Food and Drug Administration (FDA) approved Perindopril Erbumine tablet for the treatment of high blood pressure (hypertension). These tablets are manufactured by Aurobindo Pharmaceuticals.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/angiotensin-converting-enzymes-ace-inhibitors-market-2746

Browse 23 Market Data Tables and 19 Figures spread through 163 Pages and in-depth TOC on "Angiotensin Converting Enzymes (ACE) Inhibitors Market, by Drugs (Benazepril, Perindopril, Trandfolapril, Captopril, Enalapril, Lisinopril, Ramipril, and Others), by Application (Hypertension, Coronary Artery Disease, Heart Failure, Chronic Kidney Disease, Scleroderma, and Migraine), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Key players in the market are focused on launching new products for the treatment of hypertension. For instance, in July 2018, Pharmascience Inc. launched Trandolapril (ACE inhibitor) for the treatment of mild to moderate hypertension. In the case of mild to moderate hypertension, the drug can be used alone or in combination with thiazide diuretics. Trandolapril is also used for the treatment of myocardial infraction. Moreover, in January 2017, Silvergate Pharmaceuticals, Inc. launched Epaned (containing Enalapril), an oral solution, for the treatment of hypertension, symptomatic heart failure, and asymptomatic left ventricular dysfunction in adult and children. Therefore, increasing launch of new products is expected to support growth of the ACE inhibitors market. Increasing number of studies related to ACE inhibitors for the treatment of hypertension is also expected to propel the market growth during the forecast period. For instance, in February 2018, University of Munich initiated clinical phase III study to determine the effects of amlodipine and other blood pressure lowering agents (such as Losartan and Atenolol) on micro vascular function in small vessel disease. This study is expected to complete in September 2020.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2746

Key Takeaways of the Angiotensin Converting Enzymes (ACE) Inhibitors Market:

The global angiotensin converting enzymes (ACE) inhibitors market is expected to witness a CAGR of 0.8% during the forecast period (2018 – 2026), owing to increasing product launch for the treatment of hypertension and congestive heart failure

Among regions, North America is expected account for the largest market share in the angiotensin converting enzymes (ACE) inhibitors market. Increasing prevalence of hypertension is expected to boost the market growth in the region. For instance, according to American Heart Association (AHA), January 2018, per year 100 million people suffer from hypertension in the U.S.

Major players operating in the global angiotensin converting enzymes (ACE) inhibitors market, include, Pfizer, Inc., AstraZeneca Pharmaceutical Company, Novartis AG, Daiichi Sankyo Company, Ltd., United Therapeutics Corporation, Sanofi S.A., Johnson & Johnson Services, Inc., Merck KGaA, Takeda Pharmaceutical Company, and Bayer AG.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2746

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
mailto:[email protected]
U.S. Office:
Name: Mr. Shah
Coherent Market Insights 1001 4th Ave,
# 3200 Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737